|
(P1798) |
Chronic disease comorbidity of coronary heart disease and the impact on healthcare usage and productivity loss |
| |
|
M.-I. Murray, I. Thalmann, E. Mossialos, A. M. Zeiher (Frankfurt am Main; London, UK) |
|
(P1800) |
Welchen Einfluss hat ein strukturiertes Behandlungsprogramm (DMP) auf die Einstellung der kardiovaskulären Risikofaktoren bei jungen Infarktpatienten? |
| |
|
A. Fach, H. Wienbergen, R. Osteresch, T. Backhaus, J. Schmucker, E. Fiehn, J. Stehmeier, R. Hambrecht (Bremen) |
|
(P1801) |
Consequent Use of Available Oral Lipid Lowering Agents Would Bring the Majority of High-Risk Patients With Coronary Heart Disease to Recommended Targets: An Estimate Based on the DYSIS II Study |
| |
|
A. K. Gitt, D. Lautsch, G. De Ferrari, M. Horack, P. Brudi, J. Ferriéres, für die Studiengruppe: DYSIS Investigators (Ludwigshafen am Rhein; Kenilworth, US; Pavia, IT; Toulouse, FR) |
|
(P1802) |
Better LDL-Cholesterol-Target Attainment in Patients with ACS and Type 2 Diabetes – Results of DYSIS II ACS |
| |
|
A. K. Gitt, D. Lautsch, M. Horack, J. Ferriéres, für die Studiengruppe: DYSIS Investigators (Ludwigshafen am Rhein; Kenilworth, US; Toulouse, FR) |
|
(P1803) |
Dose reduction, oral administration and order of intake to preserve aspirin antiplatelet effects in patients with chronic artery disease |
| |
|
L. K. Dannenberg, A. Achilles, D. Naguib, S. Zako, R. M'Pembele, C. Helten, M. Pöhl, P. Mourikis, A. Ayhan, B. Knoop, T. Zeus, M. Kelm, T. Hohlfeld, A. Polzin (Düsseldorf) |